VYLOY DIN 02563916
Status: Marketed
Holder: ASTELLAS PHARMA CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | ZOLBETUXIMAB 300 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FX31 ZOLBETUXIMAB |
|---|
| Original market date | 03-Jun-2026 |
|---|
| Current status date | 03-Jun-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Astellas Pharma Canada Inc — licence 101369, currently licensed, last inspection rating C (2026-04-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ZOLBETUXIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02553996 | VYLOY | ASTELLAS PHARMA CANADA INC | Powder For Solution | ZOLBETUXIMAB 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36555 | 2025-12-16 | Supplement to a New Drug Submission (SNDS) | Addition of a new presentation |
Request a quote for VYLOY
How to read a Canadian DIN record